President Barack Obama’s 2015 budget, unveiled Tuesday, is playing to poor reviews from biopharma.
Adhering to the discretionary spending caps agreed to by Congress, the budget includes slight funding bumps for the FDA and National Institutes of Health (NIH), but it’s not enough, according to several organizations.
The budget calls for a 1 percent increase in tax dollars for both agencies, although the FDA would effectively see an 8 percent increase in funding due to annual increases in user fees and the addition of proposed food safety user fees. If Congress were to support the president’s separate Opportunity, Growth and Security Initiative, the NIH would see a 4 percent funding increase. (See BioWorld Today, March 5, 2014.)
“This budget proposal would actually weaken the FDA in certain areas,” Kasey Thompson, president of the Alliance for a Stronger FDA, said, noting that the agency is in the process of implementing